Almac Sciences provides innovative chemistry solutions from drug discovery to commercialisation. Capabilities include process r&d, tox and API supplies, custom manufacturing, analytical services, GMP and non-GMP peptide and protein synthesis, biocatalysis, 14C radiolabelling, potent and cytotoxic compound synthesis, and solid state services.
Almac has launched "rapidd" - an early stage development package taking lead drug development candidates to Phase I regulatory submission in under 12 months. The rapidd package enables flexible approaches to client requirements and integrated drug development to CTA, FIM or POC.
2010 will see the opening of Almac's North American headquarters where Almac Sciences will offer a wide range of analytical support services for drug substance and drug product and a complete solid state services facility utilising state-of-the-art r&d technologies.
